2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Endocrine
1
Dermatologic
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Interventions
Cisplatin
631
Radiotherapy
339
pembrolizumab
329
Cetuximab
284
Docetaxel
226
Radiotherapy, Intensity-Modulated
221
Fluorouracil
199
Carboplatin
198
Paclitaxel
161
Nivolumab
145
Gemcitabine
125
Magnetic Resonance Spectroscopy
99
Radiation
91
Drug Therapy
86
Capecitabine
77
toripalimab
75
Surveys and Questionnaires
73
Surgical Procedures, Operative
72
Biopsy
62
durvalumab
61
Chemoradiotherapy
52
Blood Specimen Collection
52
Cyclophosphamide
50
Specimen Handling
47
camrelizumab
46
Radiosurgery
46
Erlotinib Hydrochloride
46
Standard of Care
44
130-nm albumin-bound paclitaxel
44
tislelizumab
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adalimumab
×
Head & Neck
×
Clear all
NCT02516774
2016-01-26
TAM-RT
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
Withdrawn